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Plasminogen activator inhibitor-1 (PAI-1) is the primary inhibitor of plasminogen activators (uPA
and tPA) and thus plays a central role in ﬁbrinolysis. The spontaneous insertion of its reactive centre
loop (RCL) into b-sheet A is responsible for its irreversible conversion into the inactive latent form.
In this study, we used two peptides mimicking residues P14–P9 and P8–P3 of the RCL so as to under-
stand this dynamic process. We show that both peptides inhibit the formation of PAI-1/uPA and PAI-
1/tPA complexes via two different mechanisms. Targeting the N-terminal part of the loop induces
the cleavage of PAI-1 by the proteases uPA/tPA while targeting its C-terminal part greatly favors
the irreversible formation of latent PAI-1.
Structured summary of protein interactions:
PAI-1 and uPA bind by comigration in gel electrophoresis (View interaction)
tPA and PAI-1 bind by comigration in gel electrophoresis (View interaction)
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Serpins represent the largest family of serine protease inhibitors
sharing a typical structural architecture despite their modest se-
quence similarity. They are present in all branches of life and are
particularly abundant in human blood [1,2]. Due to their dynamic
native state and their high speciﬁcity, they are involved in the reg-
ulation of several proteolytic pathways [3]. Over the years, the elu-
cidation of numerous crystal structures revealed that serpins are
folded into a metastable native state [4]. In this state, the serpins
expose a large ﬂexible loop (around 20 residues) called reactive
centre loop (RCL) that confers the speciﬁcity for the targeted serine
protease [5]. The RCL acts as a lure since the peculiar primary se-
quence is recognized by the protease which will try to cleave the
loop between residues numbered P1 and P10. Once they encounter
their speciﬁc targeted protease, serpins are able to undergo a dra-
matic folding change towards a more thermodynamically stable
conformation in order to trap the protease into an inactive confor-
mation. After the formation of the Michaelis complex, cleavage of
the bond P1–P10 by the protease occurs and a covalent acyl–
enzyme intermediate is formed. Consequently the RCL is rapidlychemical Societies. Published by E
ibitor type-1; RCL, reactive
or; tPA, tissue-type plasmin-incorporated as a new central b-strand into the serpin A b-sheet.
This leads to the translocation of the covalently attached protease
to the other side of the serpin (around 70 Å away) and subsequent
distortion of the protease active site. As a ﬁnal result, the protease is
irreversibly trapped in an inactive state, demonstrating the suicidal
nature of the serpin mechanism.
Plasminogen activator inhibitor-1 (PAI-1) is a member of the
serpin superfamily [6,7]. PAI-1 inactivates tissue- and urokinase-
type plasminogen activators (tPA and uPA) therefore playing a cen-
tral role in the ﬁbrinolytic system and thus in various processes
like vascular thrombolysis [8], neovascularization or metastasis
[9]. Among the serpin family PAI-1 is unique by the possibility that
the RCL can insert spontaneously into b-sheet A without any pro-
tease involvement [7]. Thus besides the active inhibitory state,
PAI-1 can convert irreversibly into the so called latent (inactive)
form with a half-life between 1 and 2 h in physiological conditions
(Fig. 1) [10]. It has been previously hypothesized that a pre-latent
conformation of PAI-1 exists in equilibrium with the active state.
Indeed, several antibodies have been found to accelerate the la-
tency transition [11–13]. This effect cannot be explained by the
stabilization of the latent form since the transition is an irrevers-
ible process. It has therefore been suggested that the antibodies
possess a high afﬁnity for the pre-latent intermediate. By mapping
the epitopes of these antibodies they characterized the pre-latent
state by a partial insertion of the N-terminal residues of the RCL
at the entrance of the b-sheet A and partial detachment of b-strandlsevier B.V. All rights reserved.
Fig. 1. Ribbon representation of the structure of latent PAI-1 (PDB accession
number 1DVN) [10]. In this form, the RCL is inserted as strand 4 in b sheet A with
residues P14–P9 colored in green and residues P8–P3 in red. The hF helix and the
loop connecting the hF helix to the S3A strand of b sheet A are shown in pink. The
hB helix is colored in orange.
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native state of PAI-1 in which the bottom of b-sheet A is closed
whereas the top is partly open to allow partial insertion of the
RCL up to residue P11 [15]. It was also suggested that further inser-
tion of the loop beyond this point would accelerate the irreversible
transition towards the latent form.
In this work, we used two RCL mimicking hexapeptides dividing
the loop in two equal parts: RCLp14-9 (TVASSS) corresponds to res-
idues P14-P9 of the RCL and RCLp8-3 (TAVIVS) corresponds to res-
idues P8–P3. We show that both peptides are able to hinder the
formation of the complex between PAI-1 and uPA/tPA. Moreover
we demonstrate that each peptide acts via a different inhibition
mechanism. The insertion of peptide RCLp14-9 in the top of the
b-sheet A of PAI-1 induces the substrate behavior of the serpin.
In contrast we show for the ﬁrst time that the insertion of peptide
RCLp8-3 in the bottom of the b-sheet A greatly favors the irrevers-
ible formation of latent PAI-1.
2. Materials and methods
2.1. Proteins and reagents
uPA (urokinase, high molecular weight) was from Calbiochem
and tPA (Alteplase) from Boehringer Ingelheim (Actilyse). Chromo-
genic substrates S-2444 and S-2288 for uPA and tPA respectively
were from Chromogenix (Instrumentation Laboratory, Milano,
Italy). Puriﬁed peptides RCLp14-9 (Ac-TVASSS) and RCLp8-3 (Ac-
TAVIVS) corresponding to residues P14-P9 and P8-P3 of the PAI-1
RCL respectively were from GenScript USA, Inc and kept at
70 C in 2,2,2-Triﬂuoroethanol (TFE) (Sigma–Aldrich, Inc.) at a
10 mM concentration. Porcine pancreatic elastase type I (36 mg/
ml) was from Sigma–Aldrich, Inc.
2.2. PAI-1 cloning, production and puriﬁcation
Recombinant PAI-1 was produced in Escherichia coli BL21 cells.
PAI-1 gene was cloned into pCold I vector (Takara Bio Inc.) betweenBamH1 and NdeI restriction sites and produced at 15 C after
induction with 1 mM IPTG in order to limit the latency transition.
After cell disruption, (His)6-tagged soluble PAI-1 was puriﬁed in
one step on a HiTrap Chelating HP column (GE Healthcare) loaded
with Ni2+ ions. Puriﬁed PAI-1 was dialyzed and stored at 4 C in
acetate buffer 10 mM, NaCl 1 M, pH 5.6 to ensure a long conserva-
tion of the active form.
2.3. PAI-1 inactivation by RCL peptides
For end point assays, 1.5 ll of PAI (4 lM) was incubated at room
temperature for 1 h in PBS buffer (78.5 ll) without or with 5 ll of
RCLp14-9 or RCLp8-3 peptide, previously dried directly in the well
(0.5 mM ﬁnal concentration). TFE only was also dried as a control.
PAI-1 activity was measured via the residual uPA activity by addi-
tion of 10 ll of uPA (0.15 lM), further incubation for 15 min at
37 C and a ﬁnal addition of 10 ll of S-2444 chromogenic substrate
in PBS buffer. Activity was followed by measuring the absorbance
at 405 nm. For PAI-1 inactivation assays, PAI-1 (2 lM) was incu-
bated at 37 C with/without RCLp14-9 or RCLp8-3 peptide
(1 mM). Each 600 s, an aliquot (5 ll) was added in a well contain-
ing 10 ll of uPA at a concentration of 0.35 lM in PBS buffer. After
600 s of incubation, 85 ll of S-2444 chromogenic substrate in PBS
buffer were added and uPA activity was measured after 600 s. As
previously described [16], in large excess of peptide the reaction
can be characterized by a single exponential decay of active PAI-
1. Consequently, data were ﬁtted on a monoexponential function
to determine the ﬁrst order constant rate of PAI-1 inactivation, ki-
nact. Control experiments performed without peptide allowed
determination of the ﬁrst order constant rate of PAI-1 spontaneous
inactivation due to latency transition, klat. Finally, second-order
rate constant of association between PAI-1 and RCL peptides, kassoc,
were calculated according to Eq. (1) previously described [16],
kinact ¼ klat þ kassoc½peptide0 ð1Þ
where [peptide]0 is the initial concentration of the peptide. All sam-
ples were visually checked to ensure that RCL peptides were not
precipitated at these concentrations.
2.4. In vitro clot lysis assays
Clot lysis assays were performed in a 96-well microtiter plate.
When necessary, 10 ll of peptide from stock solutionwere dried di-
rectly in a well. Recombinant PAI-1 (1 ll, 4.5 lM) was then added
as well as 50 ll of a buffer containing 10 mM Tris, 0.01% Tween
20, pH 7.5. After 10 min incubation at 37 C pooled human plasma
(30 ll) was added and the plate was further incubated for 10 min at
37 C. Clot formation was initiated by adding 20 ll of Tris buffer
containing CaCl2 (53 mM). When 2 ll of tPA (Alteplase, 0.11 lM)
were included in the assay, clot lysis was completed within
30 min in the absence of PAI-1. This was monitored by optical
absorbance at 405 nm in a Victor X3 plate reader (Perkin Elmer).
Dried TFE only had no effect on clot formation or lysis (not shown).
2.5. Effect of RCL peptides on PAI-1/uPA and PAI-1/tPA complexes
formation
The effect of RCL peptides was determined by incubating PAI-1
(2 lM) with/without RCLp14-9 or RCLp8-3 peptide (1 mM) for 1 h
at room temperature in PBS buffer. uPA (0.35 lM) or tPA (Alteplase
0.32 lM) were then added and further incubated at 37 C for
15 min. Reaction was stopped by reducing SDS–PAGE and the gels
were stained using the Silver Stain Plus kit from Bio-Rad Laborato-
ries. Dried TFE only had no effect on complexes formation (not
shown). Quantiﬁcation of gels was performed using ImageJ soft-
ware (http://rsbweb.nih.gov/ij/).
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Selective cleavage of active PAI-1 by the Elastase was observed
on SDS–PAGE. PAI-1 (2 lM) was incubated with/without RCLp14-9
or RCLp8-3 peptide (1 mM) for 15 min at 37 C and the Elastase
(1.4 lM) was then added and further incubated 15 min at 37 C.
Reaction was stopped by reducing SDS–PAGE and the gels were
stained using the Silver Stain Plus kit from Bio-Rad Laboratories.
Dried TFE only had no effect on PAI-1 latency transition (not
shown). Quantiﬁcation of gels was performed using ImageJ soft-
ware (http://rsbweb.nih.gov/ij/).
2.7. Thermal denaturation recorded by intrinsic ﬂuorescence
Heat-induced unfolding was recorded using an SML-AMINCO
Model 8100 spectroﬂuorometer (Spectronic Instruments) at an
excitation wavelength of 280 nm, an emission wavelength of
330 nm and at a scan rate of 1 C/min using a programmed water
bath Lauda Ecoline RE306. Data were normalized using the pre-
and post-transition baseline slopes. Experiments were performed
at similar PAI-1 concentrations (0.5 lM) with 100 lM of RCL pep-
tides when necessary in acetate buffer 10 mM, NaCl 1 M, pH 5.6 in
order to avoid fast and spontaneous PAI-1 inactivation or precipi-
tation. Native PAI-1 was incubated at 37 C for 1 h with/without
each RCL peptide before thermal denaturation and latent form of
PAI-1 was obtained by incubating the native PAI-1 at 37 C for at
least 48 h prior the unfolding experiment.
3. Results
3.1. PAI-1 inactivation by RCL peptides
PAI-1 inhibitory activity on uPA and tPA has been determined
using speciﬁc chromogenic substrates for both proteases, S-2444
and S-2288 respectively (Chromogenix). As expected, the presence
of native PAI-1 clearly reduces uPA and tPA (not shown) proteolytic
activities (Fig. 2). In contrast, when one of the RCL mimickingFig. 2. Proteolytic activity of uPA towards the chromogenic substrate S-2444
measured at 25 C. Protease activity was measured after 60 min by reading the Abs
at 405 nm. The addition of PAI-1 inhibits the proteolytic activity while the addition
of PAI-1 inhibitory peptides RCLp14-9 or RCLp8-3 (0.5 mM ﬁnal concentration)
previously incubated for 1 h with PAI-1 restores the activity of uPA. Dried TFE
without peptide was used as a control. Data are means with SD (n = 3).peptides was supplemented in the reaction buffer, uPA and tPA
activities were restored therefore demonstrating the inhibitory ef-
fect of the peptides on PAI-1. Its inactivation was also followed at
37 C by monitoring the residual uPA-inhibiting activity (Fig. 3). In
our control conditions, PAI-1 exhibits a half-life of 4.2 ± 0.7 h (Ta-
ble 1) and an inactivation constant of 4.6  105 s1. The inactiva-
tion constant is about 20-fold increased in the presence of RCLp8-3
peptide and about 30-fold increased with RCLp14-9. The inactiva-
tion constant of 1.3  103 s1 obtained for RCLp14-9 (TVASSS) is
in good agreement with previously published values calculated
for TVASS and TVASSSTA peptides [15]. However, the new
RCLp8-3 peptide exhibits a slightly lower inactivation constant as
well as a lower rate constant of association with PAI-1 (Table 1).
3.2. In vitro clot lysis assays
We also tested the effect of RCL peptides on clot lysis assays
containing human plasma (Fig. 4). As expected, ﬁbrin clot is lysed
by tPA and the addition of its physiological inhibitor PAI-1 stabi-
lizes the clot during all the experiment. Interestingly, the addition
of both RCL peptides signiﬁcantly restores the ability of tPA to lyse
the clot with RCLp14-9 being more effective than RCLp8-3. Once
more, RCL peptides demonstrate their ability to inhibit or inacti-
vate PAI-1.
3.3. RCL peptides binding effects on PAI-1 interaction with uPA/tPA
It has been shown by crystallography that the slightly shorter
TVASS peptide is able to occupy the cleft naturally occupied by
RCL P14-P10 residues in latent or cleaved forms of PAI-1 [17], i.e.
when they form a part of the supplemental s4A b-strand in b-sheet
A. As a result, it prevents the insertion of the RCL when PAI-1
encounters its target protease therefore allowing the complete
cleavage of the serpin. It is highly probable that the extra Ser res-
idue of the RCLp14-9 peptide (TVASSS) does not modify signiﬁ-
cantly this behavior and consequently it will also induce the
appearance of the cleaved substrate form of PAI-1 during the reac-
tion with uPA or tPA. In order to investigate the behavior of PAI-1
in the presence of each RCL peptides, we incubated PAI-1 for 1 h
with either RCLp14-9 or RCLp8-3 prior addition of the target pro-
teases. The result of their interaction is observed by SDS–PAGEFig. 3. PAI-1 (2 lM) inactivation followed at 37 C (d) and in the presence of 1 mM
of RCLp14-9 () or RCLp8-3 peptide (j). PAI-1 inactivation was followed by
measuring the residual proteolytic activity of uPA towards the chromogenic
substrate S-2444. Data were ﬁtted on monoexponential curves in order to
determine the ﬁrst order constant rates of PAI-1 inactivation, kinact (Table 1). PAI-
1 was completely inactivated after 1 h in the presence of RCL peptides. Data are
means with SD (n = 3).
Table 1
PAI-1 inactivation by RCL peptides.
kinact (s1) kassoc (M1s1)
PAI-1 4.6 (±0.8)  105 /
PAI-1 + RCLp14-9 13.0 (±1.0)  104 1.254 (±0.1)
PAI-1 + RCLp8-3 9.0 (±0.7)  104 0.854 (±0.07)
Fig. 4. In vitro clot lysis assays. Clot formation was initiated by adding Tris buffer
containing CaCl2 (d) and followed by reading the absorbance at 405 nm. Fibrin clot
was completely lysed by the addition of tPA ( ) (2.2 nM) while the addition of its
physiological inhibitor PAI-1 (N) (45 nM) stabilizes the clot. The addition of
peptides 1 mM RCLp14-9 (), RCLp8-3 (.) or both of them (j) clearly restore the
hydrolyzing activity of tPA by inhibiting the PAI-1 function. One representative
experiment of three is shown.
Fig. 5. RCL peptides binding effects on PAI-1 interaction with uPA or tPA. PAI-1
(2 lM) was incubated for 1 h without or with either RCLp14-9 or RCLp8-3 peptide
(1 mM) prior the addition of uPA or tPA. After 15 min of incubation at 37 C, the
samples were analyzed by reducing SDS–PAGE and silver staining. One represen-
tative experiment of three is shown. Quantiﬁcation of the bands is shown in the
bottom panel.
Fig. 6. RCL peptides binding effects on latency transition of PAI-1. PAI-1 (2 lM) was
incubated with/without RCLp14-9 or RCLp8-3 peptide (1 mM) for 15 min at 37 C.
Elastase (1.4 lM) was then added and after 15 min of incubation at 37 C, the
samples were analyzed by reducing SDS–PAGE and silver staining. One represen-
tative experiment of three is shown. Quantiﬁcation of the bands is shown in the
bottom panel.
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tides inhibit the formation of PAI-1/uPA and PAI-1/tPA complexes
although RCLp14-9 (lanes 4 and 8) is more effective than RCLp8-
3 (lanes 5 and 9). More important is the observation thatRCLp14-9 clearly induces a higher amount of cleaved PAI-1 in com-
parison with RCLp8-3. Accordingly, it appears that the two RCL
peptides would inhibit PAI-1 via two different mechanisms of ac-
tion. We therefore checked the hypothesis that RCL peptides, espe-
cially RCLp8-3, could accelerate the conversion of PAI-1 to the
latent form therefore protecting the loop from a cleavage by the
proteases.
3.4. RCL peptides binding effects on latency transition of PAI-1
Porcine pancreatic elastase is a well characterized serine prote-
ase. It is known that elastase is able to cleave the reactive centre
loop of PAI-1 between the P4 Val and P3 Ser residues [18]. Interest-
ingly elastase is able to attack the loop only in the active conforma-
tion of PAI-1, i.e. when the loop is exposed to the solvent and not
when it is inserted in b-sheet A as in the latent form. To examine
if the RCL peptides had an effect on the PAI-1 latency transition
process, we incubated PAI-1 with the RCL peptides for 1 h at room
temperature before adding the elastase for 20 min. The same
experiments were also performed at 37 C and the resulting pro-
tein mixes were deposited on a SDS–PAGE (Fig. 6). While
RCLp14-9 had no effect on the latency transition, RCLp8-3 clearly
accelerated the formation of the latent form of PAI-1 leading to
the complete disappearance of the elastase-cleaved band on the
gel. It is worth mentioning that RCLp14-9 had the opposite effect.
As previously described [17] the insertion of this peptide as an ex-
tra b-strand in the b-sheet A of PAI-1 prevents the insertion of the
RCL and consequently slow down the conversion to the latent
form, even at 37 C. Therefore it is unambiguous that both RCL
mimicking peptides are acting differently on PAI-1 underlying
the diverse role and function of each fraction of the RCL.
3.5. RCL peptides binding effects on PAI-1 stability
A signiﬁcant difference in thermodynamic stability between the
different forms of PAI-1 has been previously described. Using CD
spectroscopy and Differential Scanning Calorimetry it has been
shown that the melting temperature Tm of the latent PAI-1 is
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of RCL peptides insertions into PAI-1 b-sheet A and/or the induc-
tion of its latency transition, we compared the thermal denatur-
ation of different forms of PAI-1 incubated or not with RCL
peptides (Fig. 7). In our conditions, active PAI-1 exhibits a Tm of
57.8 C whereas the latent form (48 h of incubation at 37 C) is
clearly stabilized with a Tm of 70.6 C. Remarkably we found that
only 1 h of incubation of PAI-1 at 37 C with either RCLp14-9 or
RCLp8-3 peptide is sufﬁcient to obtain the same level of stabiliza-
tion with melting temperatures of 69.9 and 70.1 C respectively.
4. Discussion
Since the publication in 1995 that a 14 amino acid length pep-
tide corresponding to the PAI-1 reactive centre loop residues
(P14-P1) can rapidly inhibit PAI-1 function [20], several studies
used RCL mimicking peptides to successfully inactivate PAI-1
[16]. In 1998, Xue et al. published the crystal structure of a complex
formed between a stable mutated PAI-1 (A335E) with two mole-
cules of RCL peptides (TVASS) corresponding to residues P14-P10
[17]. Both molecules were found inserted between b strands 3A
and 5A and occupied the same space occupied by P14–P10 and
P6–P2 residues in the latent form. Thus it was clearly demonstrated
that small RCL mimicking peptides were able to induce the struc-
tural rearrangements of PAI required to accommodate the peptides
in b sheet A. Several studies showed that the binding of RCL mim-
icking peptides prevents the RCL insertion after protease engage-
ment. This leads to the blocking of the protease translocation and
inhibition, allowing the protease to completely cleave PAI-1 as a
substrate. Kvassman et al. concluded that peptide binding and for-
mation of the latent inhibitor aremutually exclusive events [16]. To
our knowledge, all these studieswere concentrated on the proximal
part of the RCL starting at position P14 and no data was available
concerning the distal part of the loop alone. That was the starting
point of this study and our two RCL peptides were chosen to cover
a large part of the RCL, i.e. 12 residues from P14 to P3. The loop was
divided into two equal parts of 6 residues, RCLp14-9 (TVASSS) for
the proximal fraction and RCLp8-3 (TAVIVS) for the distal fraction
of the RCL (Fig. 1).
RCLp8-3 peptide showed for the ﬁrst time that targeting the
distal end of the RCL is enough and effective to inactivate PAI-1.Fig. 7. Heat-induced unfolding of PAI-1 recorded by ﬂuorescence emission. From
left to right: Active form of PAI-1 (d) (Tm = 57.8 ± 0.15 C), PAI-1 + RCLp14-9 (red)
(Tm = 69.9 ± 0.16 C), PAI-1 + RCLp8-3 (green) (Tm = 70.1 ± 0.25 C) and latent form
of PAI-1 (blue) (Tm = 70.6 ± 0.17 C). Experiments were performed at similar PAI-1
concentrations (0.5 lM), with 100 lM of RCL peptides when necessary in acetate
buffer 10 mM, NaCl 1 M, pH = 5.6. One representative experiment is shown for each
curve.From a kinetic point of view, RCLp8-3 demonstrated to be slightly
slower than its N-terminal counterpart in all our inactivation
experiments. This was also noticeable on SDS–PAGE where a small
part of PAI-1 was still able to form a complex with tPA or uPA
(Fig. 5) therefore revealing an incomplete inactivation of PAI-1 by
RCLp8-3 in the lap time of these experiments.
The relative slower ability of RCLp8-3 in comparison with
RCLp14-9 to inactivate PAI-1 could be explained in different ways:
ﬁrstly, a possible slower rate of insertion of the peptide in b sheet A
and secondly an additional slow event subsequent of the peptide
insertion and leading to the inactivation of PAI-1. From a structural
point of view, the insertion sites of both peptides can be compared
by studying their respective location in the latent form of PAI-1
(Fig. 1). The insertion site for the RCLp14-9 peptide is open and
easily accessible from the environment. It must remain accessible
if we keep in mind the existence of the pre-latent form of PAI char-
acterized by a partial insertion of the N-terminal residues of the
RCL loop at the entrance of the b-sheet A [11,15]. In contrast the
insertion site for RCLp8-3 peptide is located in a region buried be-
hind the hF helix and the loop connecting the hF helix to the S3A
strand of b sheet A. Accordingly it will be more difﬁcult for
RCLp8-3 peptide to penetrate the PAI-1 structure and reach the tar-
geted part of b sheet A due to the sterical barrier. As a result the
insertion rate of peptide RCLp8-3 will be slower in comparison
with RCLp14-9.
As discussed previously, insertion of peptides in the entrance of
b sheet A leads to the complete cleavage of PAI-1 by its targeted
protease. We propose here a model for the distinct mechanisms
of action of RCL peptides on PAI-1 (Fig. 8). While RCLp14-9 peptide
noticeably increased the amount of cleaved PAI-1 (Fig. 5), RCLp8-3
had no effect on the resulting amount of cleaved PAI-1. Moreover,
elastase experiments demonstrated the complete latency transi-
tion induced only by the RCLp8-3 peptide (Fig. 6). Thus the irre-
versible active?latent transition, inevitably accompanied by the
release of the peptide previously inserted in b sheet A, could be
the rate limiting step in the inactivation of PAI-1 (Fig. 8).
Knowing (1) that the latent form of PAI-1 is largely stabilized
compared to active PAI-1 and (2) that we were convinced that both
RCL peptides were able to ﬁt into the PAI-1 b-sheet A, we decided
to measure the serpin stability in the presence of RCL peptides.
Notably, we found a stabilization effect equal to the latent form
demonstrating that peptides insertion is actually a thermodynam-
ically favorable process mimicking the latency transition. As a con-
sequence all our attempts to remove the peptides from PAI-1 either
by dilution or dialysis were vain and their insertion can be consid-
ered irreversible (Fig. 8). However, it remains to be demonstrated
that the insertion of its own loop can eject and replace the inserted
peptide to take its natural place in the b-sheet A. If it would not be
the case, the ﬁnal PAI-1 form after RCLp8-3 insertion could contain
only a partially inserted RCL (not cleavable by uPA, tPA or elastase)
with still the peptide in the b-sheet (not shown in the model pre-
sented in Fig. 8) instead of a latent form with a released peptide.
In conclusion, we propose that the RCL can be divided in two
equal parts with two different functions. The proximal part of
the RCL is responsible for the metastable nature of the serpin
and is primordial for the inhibitory activity of PAI-1. It must be rap-
idly inserted in b sheet A after encountering the targeted protease
in order to win the kinetic competition towards the inactivation of
the protease rather than the cleavage of PAI-1. On the other side,
the distal part of the RCL is involved in the latency transition of
PAI-1. If the opening process of b sheet A passes the position P8,
the PAI-1 structure accommodates the whole RCL and as a conse-
quence is irreversibly converted to the latent form. Therefore the
C-terminal end of the RCL and its insertion site in the latent form
may constitute a suitable target for drugs aiming to inactivate
PAI-1 or to avoid serpins polymerization.
Fig. 8. Schematic representation of distinct mechanisms of action of RCL peptides on PAI-1. Panel A: In the absence of RCL peptides, PAI-1 interaction with uPA leads to the
irreversible formation of the covalent complex PAI/uPA. Panel B: The insertion of peptide RCLp14-9 in the entrance of b sheet A leads to the complete cleavage of PAI-1 by the
protease uPA. Panel C: The insertion of peptide RCLp8-3 in the bottom of b sheet A induces the irreversible transition to the latent form of PAI-1 without any cleavage.
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formation of ordered polymers. These polymers lead to diseases
called serpinopathies and a nice review can be found in [21]. For
years, the polymerization process remained explained by the inser-
tion of the RCL of one serpin molecule into the A sheet of another,
and so on. The so called ‘‘A-sheet polymerization’’ model has been
recently challenged by Yamasaki et al. [22,23] who suggested that
the P8-P6 region is only a small part of an extensive domain swap
involving the insertion of strands 4 and 5 of one monomer into the
b sheet A of another. However, in some cases small RCL mimicking
peptides were sufﬁcient to block serpin polymerization. Z a1-anti-
trypsin polymerization was blocked by a P8–P3 peptide [24] while
a P7-P3 peptide was able to block the antithrombin polymerization
[25]. These results demonstrate the importance to study the effect
of RCL mimicking peptides targeting the C terminal end of the RCL
and its insertion site.
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